Compare IAC/Interactivecorp (PPLI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

PPLI trades at $38.38, down 1.56% in the last session, with a bearish technical signal but attractive valuation ratios including a P/E of 6.49 and P/B of 0.56. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by gains from its MGM stake, though revenue declined to $2.39B in 2025. The company is focusing on monetizing non-core assets and capital allocation toward its media business and MGM holdings, as highlighted in recent conference presentations.

The outlook is mixed: strong analyst support with a $58.80 consensus price target and 69% buy ratings offers upside, but risks include volatile earnings, declining revenue trends, and a shareholder investigation. Investors should weigh the deep valuation discount against execution challenges in asset sales and digital growth.

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.